Mirum Pharmaceuticals, Inc. (MIRM) experienced a pre-market plunge of 5.17% on Thursday.
The movement follows a series of analyst price target adjustments for the healthcare company. Several firms, including Stifel, Raymond James, and Morgan Stanley, raised their price targets on Mirum Pharmaceuticals. However, RBC lowered its target slightly to $128 from $130 while keeping an Outperform rating.
According to FactSet data, the stock maintains an average buy rating with a mean price target of $122.36. The mixed analyst sentiment, particularly the downward adjustment from RBC, appears to have contributed to the pre-market decline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.